1101840-72-5

Basic information

• Product Name: 6-azaspiro[2.5]octane-6-carboxylic acid, 4-hydroxy-, 1,1-dimethylethyl ester
• Synonyms: 6-azaspiro[2.5]octane-6-carboxylic acid, 4-hydroxy-, 1,1-dimethylethyl ester;tert-Butyl 4-hydroxy-6-azaspiro[2.5]octane-6-carboxylate;4-hydroxy-6-Azaspiro[2.5]octane-6-carboxylic acid 1,1-dimethylethyl ester;6-Boc-4-hydroxy-6-azaspiro[2.5]octane
• CAS NO: 1101840-72-5
• Molecular Formula: C₁₂H₂₁NO₃
• Molecular Weight: 227.30004
• Mol File: 1101840-72-5.mol

Chemical Properties

• Boiling Point: 333.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.14±0.1 g/cm3(Predicted)
• PKA: 14.70±0.20(Predicted)
• CAS DataBase Reference: 6-azaspiro[2.5]octane-6-carboxylic acid, 4-hydroxy-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-azaspiro[2.5]octane-6-carboxylic acid, 4-hydroxy-, 1,1-dimethylethyl ester(1101840-72-5)
• EPA Substance Registry System: 6-azaspiro[2.5]octane-6-carboxylic acid, 4-hydroxy-, 1,1-dimethylethyl ester(1101840-72-5)

Safety Data

• Hazardous Substances Data: 1101840-72-5(Hazardous Substances Data)

Upstream product

• 75-11-6 diiodomethane 
• 159635-22-0 3-hydroxy-4-methylene-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 
• 593-71-5 Chloroiodomethane 
• 557-20-0 diethylzinc 
• 159635-49-1 tert-butyl 4-methylidenepiperidine-1-carboxylate 

Downstream Products

• 1103501-89-8 (S)-6-aza-spiro[2.5]octan-4-ol hydrochloride 
• 1290048-29-1 4-[4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-5-oxo-[1,4]diazepane-1-carboxylic acid benzyl ester 
• 1290048-74-6 (S)-4-[(R,S)-3-Hydroxy-4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid benzyl ester 
• 1290049-74-9 (S)-4-[(E)-3-(3-Chloro-4-fluoro-phenyl)-acryloyl]-1-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-3-oxo-propyl]-3-methyl-piperazin-2-one 
• 1290049-14-7 (S)-4-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-3-oxo-propyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid (3,4-dichloro-phenyl)-amide 
• 1290050-56-4 (S)-4-[(R,S)-3-hydroxy-4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid (3-chloro-4-trifluoromethyl-phenyl)-amide 
• 1290050-27-9 4-[4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-5-oxo-[1,4]diazepane-1-carboxylic acid (3-chloro-phenyl)-amide 
• 955082-88-9 4-hydroxy-6-azaspiro[2.5]octane 
• 1101840-74-7 4-Oxo-6-aza-spiro[2,5]octane-6-carboxylic acid tert-butyl ester 

Relevant articles and documents

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS

The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

HETEROCYCLIC COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R3, R4, R5, R6, R7, R8, R9, R10, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.